Cyclopharm's Lung Imaging Product Recognized as Preferred Agent in Draft Clinical Guideline; Shares Up 13%
MT Newswires Live
Jan 27
Cyclopharm (ASX:CYC) said its Technegas lung imaging product was recognized as a preferred ventilation agent in a new draft clinical guideline for lung imaging, according to a Tuesday filing with the Australian bourse.
The Procedure Standard and Guideline for Ventilation-Perfusion Pulmonary Scintigraphy recognized Technegas for clinical use in the US, designating it as a preferred ventilation agent when available, the filing said.
The draft guideline has been released for public consultation and will be refined for factual variations, per the filing.
Shares rose 13% in afternoon trade on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.